Response to ASX Query
Filed with ASX · · 6 pages · English
We refer to your letter dated 21 June 2021 (Letter). In response to your questions outlined in the Letter, and using the same definitions as included in your Letter, the Company provides the following information: Question 1: Does PAB consider the information to be information that a reasonable person would expect to have a material effect on the price or value of its securities? Yes. Question 2:
Earlier from Patrys
- Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
- Paper highlights PAT-DX1 as potential brain cancer treatment
- Patrys receives R&D Tax Incentive refund
- Appendix 4C - Quarterly - 31 March 2021
- New United States patent granted for Patrys deoxymab assets
Later from Patrys
- Full size deoxymab PAT-DX3 crosses the blood brain barrier
- PAT-DX1 Improves Survival in Model of Pancreatic Cancer
- Appendix 4C - Quarterly - 30 June 2021
- Market Update - PAT-DX1 Clinical Trial Preparation
- Appendix 4E and 2021 Annual Report
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys